New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
17:46 EDTMNKMallinckrodt announces settlement of Ofirmev injection patent litigation
Mallinckrodt announced that its subsidiary, Cadence Pharmaceuticals, has entered into settlement and license agreements with Fresenius Kabi USA resolving pending patent litigation involving Ofirmev injection. The companies are not disclosing specific terms of the settlement and license agreements, except that Cadence has granted Fresenius Kabi a non-exclusive right to market an intravenous acetaminophen product in the U.S. under Fresenius Kabiís NDA on December 6, 2020, or earlier under certain circumstances. Mallinckrodtís subsidiary Cadence has two patents covering Ofirmev listed in the Orange Book, the last of which will expire on June 6, 2021. Cadence had filed suit against Fresenius Kabi in January 2013.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
10:16 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:49 EDTMNKMallinckrodt reinstated with an Overweight at Barclays
Subscribe for More Information
September 16, 2014
07:30 EDTMNKCRT Capital to hold a conference
2nd Annual Investor Conference to be held in Greenwich, CT on September 16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use